Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H; LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Kjeldsen SE, et al. Among authors: nieminen ms. JAMA. 2002 Sep 25;288(12):1491-8. doi: 10.1001/jama.288.12.1491. JAMA. 2002. PMID: 12243636 Clinical Trial.
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Dahlöf B, et al. Among authors: nieminen ms. Lancet. 2002 Mar 23;359(9311):995-1003. doi: 10.1016/S0140-6736(02)08089-3. Lancet. 2002. PMID: 11937178 Clinical Trial.
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S; LIFE Study Group. Lindholm LH, et al. Among authors: nieminen ms. Lancet. 2002 Mar 23;359(9311):1004-10. doi: 10.1016/S0140-6736(02)08090-X. Lancet. 2002. PMID: 11937179 Clinical Trial.
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S; LIFE study group. Lindholm LH, et al. Among authors: nieminen ms. J Hypertens. 2002 Sep;20(9):1879-86. doi: 10.1097/00004872-200209000-00035. J Hypertens. 2002. PMID: 12195132 Clinical Trial.
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y; LIFE substudy. Ibsen H, et al. Among authors: nieminen ms. J Hypertens. 2004 Sep;22(9):1805-11. doi: 10.1097/00004872-200409000-00026. J Hypertens. 2004. PMID: 15311110 Clinical Trial.
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B; LIFE Study Investigators. Okin PM, et al. Among authors: nieminen ms. JAMA. 2004 Nov 17;292(19):2343-9. doi: 10.1001/jama.292.19.2343. JAMA. 2004. PMID: 15547161 Clinical Trial.
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Kizer JR, Dahlöf B, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Wachtell K, Edelman JM, Snapinn SM, Harris KE, Devereux RB. Kizer JR, et al. Among authors: nieminen ms. Hypertension. 2005 Jan;45(1):46-52. doi: 10.1161/01.HYP.0000151324.05355.1c. Epub 2004 Dec 6. Hypertension. 2005. PMID: 15583076 Clinical Trial.
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Reims HM, Oparil S, Kjeldsen SE, Devereux RB, Julius S, Brady WE, Fyhrquist F, Ibsen H, Lindholm LH, Omvik P, Wedel H, Beevers G, de Faire U, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Dahlöf B; LIFE Study Group. Reims HM, et al. Among authors: nieminen ms. Blood Press. 2004;13(6):376-84. doi: 10.1080/08037050410016483. Blood Press. 2004. PMID: 15771223 Clinical Trial.
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
Kjeldsen SE, Lyle PA, Kizer JR, Dahlöf B, Devereux RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn SM, Harris KE, Wedel H; LIFE Study Group. Kjeldsen SE, et al. Among authors: nieminen ms. J Clin Hypertens (Greenwich). 2005 Mar;7(3):152-8. doi: 10.1111/j.1524-6175.2005.04254.x. J Clin Hypertens (Greenwich). 2005. PMID: 15785156 Free PMC article. Clinical Trial.
460 results